Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Management
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News
  • Price Target
  • Reiteration

Analyst Views Novo Nordisk’s Upcoming Obesity Drug Data To Lay Grounds For Eli Lilly’s Tirzepatide

By Vandana Singh
Today, 10:35 PM
Cantor Fitzgerald published around 40-page deep dive ahead of Novo Nordisk A/S's (NYSE: NVO) SELECT CV outcomes study, which is guided to complete in ~mid-2023. 

AMGN

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • M&A
  • News

Novartis CEO Refutes Recent Report Of Weighing Options For Ophthalmology, Respiratory Units

By Vandana Singh
Today, 10:35 PM
Novartis AG (NYSE: NVS) said it would narrow its focus on five core therapeutic areas, including cardiovascular, immunology, neurodegenerative diseases, solid tumors, and hematology.

NVS

Read More
1 minute read
  • News
  • Rumors
  • Trading Ideas

Traders Circulate Post Suggesting Novartis AG ‘Misses On 2nd Interim For NATALEE Trial. Not A Good Sign For Differentiation Vs Abema’

By Benzinga Newsdesk
Today, 10:35 PM
https://twitter.com/pharmacreep/status/1612487217800167424

NVS

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • M&A
  • News
  • Rumors

GSK Looking For Under-Appreciated M&A Targets, Not Trying To Be Next Roche Or AstraZeneca

By Vandana Singh
Today, 10:35 PM
GSK plc (NYSE: GSK) chief commercial officer Luke Miels says the company is looking at M&A targets that are under-appreciated worth $1 billion-$2.5 billion and avoid getting into a 'bidding war.'

GSK

Read More
5 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • Legal
  • Media
  • News
  • Penny Stocks
  • Tech
  • Top Stories

Elon Musk Tells Employees Tesla Will Be ‘Most Valuable Company On Earth, Sam Bankman-Fried Set To Enter Plea On Fraud Case, Twitter ‘Should Feel Faster’: Today’s Top Stories

By Vandana Singh
Today, 10:35 PM
Reuters

$BNB

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • Legal
  • News
  • Penny Stocks

Novartis Settles Antitrust Cases Related To Generic Entry For Hypertension Drug

By Vandana Singh
Today, 10:35 PM
Novartis AG (NYSE: NVS) will pay $245 million to end antitrust litigation accusing the company of trying to delay the U.S. launch of generic versions of its Exforge, which treats hypertension to lower blood pressure and reduce the risk of strokes.

CVS

Read More
1 minute read
  • News

5 Value Stocks In The Healthcare Sector

By Benzinga Insights
Today, 10:35 PM
What are Value Stocks? A value stock traditionally has a lower price when compared to stock prices of…

ABOS

Read More
4 minute read
  • Options

10 Health Care Stocks Whale Activity In Today’s Session

By Benzinga Insights
Today, 10:35 PM
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

ALGN

Read More
1 minute read
  • Markets
  • Movers
  • Trading Ideas

A Bullish Sign Appears On Novartis’s Chart

By Benzinga Insights
Today, 10:35 PM
If history is any guide, there may be good fortune ahead for shares of Novartis (NYSE:NVS). A so-called…

NVS

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • General
  • Health Care
  • M&A
  • Movers
  • News
  • Price Target
  • Trading Ideas

Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says

By Vandana Singh
Today, 10:35 PM
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) has announced positive topline results from the pivotal Phase 3 MAESTRO-NASH biopsy trial of resmetirom. JMP has…

AZN

Posts navigation

Previous 1 2 3 … 30 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service